Wednesday, 26 August 2026European Markets

CORBION Stock Is 10% Down So Far On Friday

Loading stream...

(VIANEWS) - Shares of CORBION (AEX-Index: CRBN.AS) slid by a staggering 10.88% to €32.28 at 13:09 EST on Friday, after two sequential sessions in a row of gains. AEX-Index is jumping 0.53% to €759.17, after two successive sessions in a row of losses. This seems, up to now, a somewhat positive trend exchanging session today.

CORBION's last close was €36.22, 4.08% under its 52-week high of €37.76.

About CORBION

Corbion N.V. provides lactic acid and lactic acid derivatives, emulsifiers, functional enzyme blends, minerals, vitamins, and algae ingredients worldwide. The company offers ingredient solutions made from renewable resources for the food, home and personal care, pharmaceutical, animal nutrition, medical device, and bioplastics markets. It markets its products through a network of sales offices and distributors. The company was formerly known as CSM N.V. and changed its name to Corbion N.V. in October 2013. Corbion N.V. was founded in 1919 and is headquartered in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, CORBION has a trailing twelve months EPS of €1.06.

PE Ratio

CORBION has a trailing twelve months price to earnings ratio of 30.45. Meaning, the purchaser of the share is investing €30.45 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.81%.

Volume

Today's last reported volume for CORBION is 512345 which is 974.14% above its average volume of 47698.

Volatility

CORBION's last week, last month's, and last quarter's current intraday variation average was a positive 0.86%, a negative 0.10%, and a positive 1.31%.

CORBION's highest amplitude of average volatility was 0.92% (last week), 1.11% (last month), and 1.31% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CORBION's stock is considered to be oversold (<=20).

More news about CORBION (CRBN.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com